Revance Therapeutics - RVNC Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month target prices for Revance Therapeutics' stock. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $37.90 in the next year. This suggests a possible upside of 74.4% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.

Revance Therapeutics' stock was trading at $16.32 at the beginning of 2022. Since then, RVNC stock has increased by 33.1% and is now trading at $21.73.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our RVNC earnings forecast.

Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.05. The biopharmaceutical company had revenue of $19.75 million for the quarter, compared to the consensus estimate of $20.03 million. Revance Therapeutics had a negative net margin of 251.92% and a negative trailing twelve-month return on equity of 461.54%. During the same quarter in the prior year, the company earned ($1.34) earnings per share.

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.24%), State Street Corp (1.96%), Two Sigma Investments LP (1.36%), Jennison Associates LLC (1.47%), Jacobs Levy Equity Management Inc. (1.12%) and Rice Hall James & Associates LLC (1.23%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dwight Moxie and Mark J Foley.
View institutional ownership trends.

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVNC stock can currently be purchased for approximately $21.73.

Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $1.79 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

The company employs 495 workers across the globe.

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.